Principles of Antibiotic Therapy

  • Ellen Riccobene
  • Richard Gleckman


Antimicrobial agents are used to prevent infection, manage established infections, and treat presumptive infections. To correctly administer these compounds, clinicians must understand the indications, spectrum, pharmacodynamics, potential for drug-induced adverse reactions and drug-drug interactions, and relative cost (1). In the surgical intensive care unit (SICU), physicians must be aware of the unique pathogens and their antibiotic profiles, because patients in this setting are often seriously ill, immunosuppressed hosts who have undergone extensive surgical procedures and received numerous antibiotics.


Surgical Intensive Care Unit Asymptomatic Bacteriuria Trough Serum Concentration Infection Control Practice Advisory Committee Hospital Infection Control Practice Advisory 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Thompson RL, Wright AJ. General principles of antimicrobial therapy Mayo Clin Proc 1998; 73: 995–1006.CrossRefGoogle Scholar
  2. 2.
    Opal SM, Mayer KH, Medeiros AA. Mechanisms of bacterial antibiotic resistance. In: Mandel GL, Bennett JE, Dolin R, eds. Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Disease, 5th ed. Philadelphia: Churchill Livingstone, 2000: 236–53.Google Scholar
  3. 3.
    Ambrose PG, Owens RC Jr, Quintiliani R, Yeston N, Crowe HM, Cunha BA, Nightingale CH. Antibiotic use in the critical care unit Crit Care Clin 1998; 14: 283–308.CrossRefGoogle Scholar
  4. 4.
    Livornese LL Jr, Benz RL, Ingerman MJ, Santoro J. Antibacterial agents in renal failure. Infect Dis Clin North Am 1995; 9: 591–614.PubMedGoogle Scholar
  5. 5.
    Borrego F, Gleckman R. Principles of antibiotic prescribing in the elderly. Drugs Aging 1997; 11: 7–18.PubMedCrossRefGoogle Scholar
  6. 6.
    Philipson A. Pharmacokinetics of ampicillin during pregnancy. J Infect Dis 1977; 136: 370–6.PubMedCrossRefGoogle Scholar
  7. 7.
    Gleckman RA, Borrego F. Adverse reactions to antibiotics. Clues for recognizing, understanding, and avoiding them. Postgrad Med 1997; 101: 97–108.Google Scholar
  8. 8.
    Idsoe O, Guthe T, Willcox RR, Weck Al de. Nature and extent of penicillin side-reactions, with particular reference to fatalities from anaphylactic shock. Bull World Health Organ 1968; 38: 159–88.PubMedGoogle Scholar
  9. 9.
    Adkinson NF Jr, Wheeler B, Swabb EA. Clinical tolerance of the monobactam aztreonam in penicillin allergic subjects (abstract). 14th International Congress of Chemotherapy, June 23–28, 1985, Kyoto, Japan.Google Scholar
  10. 10.
    Gregg CR. Drug interactions and anti-infective therapies. Am J Med 1999; 106: 227–37.PubMedCrossRefGoogle Scholar
  11. 11.
    Mangram AJ, Horan TC, Pearson ML, Silver LC, Jarvis WR. Guideline for prevention of surgical site infection, 1999. Hospital Infection Control Practices Advisory Committee. Infect Control Hosp Epidemiol 1999; 20: 250–78.CrossRefGoogle Scholar
  12. 12.
    Osmon DR. Antimicrobial prophylaxis in adults Mayo Clin Proc 2000; 75: 98–109.CrossRefGoogle Scholar
  13. 13.
    Kaufman D, Haas CE, Edinger R, Hollick G. Antibiotic susceptibility in the surgical intensive care compared with the hospital-wide antibiogram. Arch Surg 1998; 133: 1041–5.PubMedCrossRefGoogle Scholar
  14. 14.
    Borrego F, Gleckman R. Preventing antibiotic treatment failure. Contemp Intern Med 1996; 8: 9–15.Google Scholar
  15. 15.
    Sobel JD, Kauffman CA, McKinsey D, Zervos M, Vazquez JA, Karchmer AW, Lee J, Thonias C, Panzer H, Dismukes WE. Candiduria: a randomized, double-blind study of treatment with fluconazole and placebo. The National Institute of Allergy and Infectious Diseases (NIAID) Mycoses Study Group. Clin Infect Dis 2000; 30: 19–24.PubMedCrossRefGoogle Scholar
  16. 16.
    Lamb HM, Figgitt DP, Faulds D. Quinupristin/dalfopristin: a review of its use in the management of serious gram-positive infections. Drugs 1999; 58: 1061–97.PubMedCrossRefGoogle Scholar
  17. 17.
    Chien JW, Kucia ML, Salata RA. Use of linezolid, an oxazolidinone, in the treatment of multidrug-resistant gram-positive bacterial infections. Clin Infect Dis 2000; 30: 146–51.PubMedCrossRefGoogle Scholar
  18. 18.
    Wong-Beringer A, Jacobs RA, Guglielmo BJ. Lipid formulations of amphotericin B: clinical efficacy and toxicities. Clin Infect Dis 1998; 27: 603–18.PubMedCrossRefGoogle Scholar
  19. 19.
    Lomaestro BM, Piatek MA. Update on drug interactions with azole antifungal agents. Ann Pharmacother 1998; 32: 915–28.PubMedCrossRefGoogle Scholar
  20. 20.
    Andriole VT. Current and future therapy of invasive fungal infections. Curr Clin Top Infect Dis 1998; 18: 19–36.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2001

Authors and Affiliations

  • Ellen Riccobene
    • 1
  • Richard Gleckman
    • 1
  1. 1.St. Joseph’s Hospital & Medical CenterPattersonUSA

Personalised recommendations